76 Chapter 3 38. Leal SL, Lockhart SN, Maass A, Bell RK, Jagust WJ. Subthreshold Amyloid Predicts Tau Deposition in Aging. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2018;38(19):4482-9. 39. Palmqvist S, Scholl M, Strandberg O, Mattsson N, Stomrud E, Zetterberg H, et al. Earliest accumulation of beta-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nature communications. 2017;8(1):1214. 40. McRae-McKee K, Udeh-Momoh CT, Price G, Bajaj S, de Jager CA, Scott D, et al. Perspective: Clinical relevance of the dichotomous classification of Alzheimer’s disease biomarkers: Should there be a “gray zone”? Alzheimer’s & dementia : the journal of the Alzheimer’s Association. 2019;15(10):1348-56. 41. Insel PS, Ossenkoppele R, Gessert D, Jagust W, Landau S, Hansson O, et al. Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer’s Disease. Frontiers in neuroscience. 2017;11:281. 42. Fakhry-Darian D, Patel NH, Khan S, Barwick T, Svensson W, Khan S, et al. Optimisation and usefulness of quantitative analysis of (18)F-florbetapir PET. The British journal of radiology. 2019;92(1101):20181020. 43. Habert MO, Bertin H, Labit M, Diallo M, Marie S, Martineau K, et al. Evaluation of amyloid status in a cohort of elderly individuals with memory complaints: validation of the method of quantification and determination of positivity thresholds. Annals of nuclear medicine. 2018;32(2):75-86. 44. Carbonell F, Zijdenbos AP, Charil A, Grand’Maison M, Bedell BJ. Optimal Target Region for Subject Classification on the Basis of Amyloid PET Images. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2015;56(9):1351-8. 45. Sakr FA, Grothe MJ, Cavedo E, Jelistratova I, Habert M-O, Dyrba M, et al. Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study. Alzheimer’s research & therapy. 2019;11(1):15-. 46. Thomas BA, Erlandsson K, Modat M, Thurfjell L, Vandenberghe R, Ourselin S, et al. The importance of appropriate partial volume correction for PET quantification in Alzheimer’s disease. European journal of nuclear medicine and molecular imaging. 2011;38(6):1104-19. 47. Schmidt ME, Chiao P, Klein G, Matthews D, Thurfjell L, Cole PE, et al. The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data. Alzheimer’s & Dementia. 2015;11(9):1050-68. 48. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain : a journal of neurology. 2009;132(Pt 5):1310-23. 49. Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, et al. Relationships between biomarkers in aging and dementia. Neurology. 2009;73(15):1193-9.
RkJQdWJsaXNoZXIy MjY0ODMw